Citations 14
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Lewczuk, Piotr , Riederer, Peter , Verbeek, Marcel M. , Dubois, Bruno , Visser, Pieter Jelle , Engelborghs, Sebastiaan , Ramı́rez, Alfredo , Parnetti, Lucilla , Jack, Clifford R. , Teunissen, Charlotte E. , Hampel, Harald , Lleó, Alberto , Jessen, Frank , Glodzik, Lidia , Leon, Mony J. de , Fagan, Anne M. , Molinuevo, José Luís , Jansen, Willemijn J. , Winblad, Bengt , Shaw, Leslie M. , Andréasson, Ulf , Otto, Markus , Mollenhauer, Brit , Wiltfang, Jens , Turner, Martin R. , Zerr, Inga , Handels, Ron , Thompson, Alexander G. , Johansson, Gunilla , Ermann, Natalia, Trojanowski, John Q. , Karaca, Ilker, Wagner, Holger, Oeckl, Patrick , Doorn, Linda van Waalwijk van, Bjerke, Maria , Kapogiannis, Dimitrios , Kuiperij, H. Bea , Farotti, Lucia , Li, Yi , Gordon, Brian A. , Vos, Stephanie J. B. , Klijn, Catharina J.M. , Nostrand, William E. Van , Schmitz, Matthias , Gallo, Carla , Mato, Andrea Lopez, Thibaut, Florence , Lista, Simone , Alcolea, Daniel , Blennow, Kaj , Kornhuber, Johannes , Thibaut, on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence, Verbeek, Marcel M , Ramirez, Alfredo , Parnetti, Lucilla , Jack, Clifford R , Lleó, Alberto , Handels, Ron , Thompson, Alexander G , Trojanowski, John Q , Gordon, Brian A , Thibaut, Florence , Alcolea, Daniel , Kornhuber, Johannes , Teunissen, Charlotte E , Turner, Martin R , Molinuevo, José Luis , O’Bryant, Sid E. , Jellinger, Kurt , Doorn, Linda Josephine Christine van Waalwijk van, Epelbaum, Stéphane , Minguillón, Carolina , Zetterberg, Henrik , Thibaut, on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence, Wiltfang, Jens , Otto, Markus
The World Journal of Biological Psychiatry | October 27, 2017 | Volume: 19 | Issue: 4 | Pages: 244-328
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
Jessen, Frank , Amariglio, Rebecca E. , Breteler, Monique M.B. , Ceccaldi, Mathieu , Chételat, Gaël , Dubois, Bruno , Dufouil, Carole , Ellis, Kathryn A. , Flier, Wiesje M. van der , Glodzik, Lidia , Harten, Argonde C. van , Leon, Mony J. de , McHugh, Pauline, Mielke, Michelle M. , Molinuevo, José Luís , Mosconi, Lisa , Osorio, Ricardo S. , Perrotin, Audrey , Petersen, Ronald C. , Rabin, Laura A., Rami, Lorena , Reisberg, Barry , Sachdev, Perminder S. , Sayette, Vincent de La , Saykin, Andrew J. , Scheltens, Philip , Shulman, Melanie , Slavin, Melissa J., Stewart, Robert , Uspenskaya, Olga, Vellas, Bruno , Visser, Pieter Jelle , Wagner, Michael , Group, Subjective Cognitive Decline Initiative (SCD‐I) Working, Boxtel, Martin P.J. van , Rentz, Dorene M. , Sperling, Reisa Anne , Stewart, Robert , Group, Subjective Cognitive Decline Initiative (SCD‐I) Working, Mielke, Michelle M , Saykin, Andrew J , Sachdev, Perminder S , van der Flier, Wiesje M , Scheltens, Philip , Molinuevo, José Luis
Alzheimer's & Dementia | May 3, 2014 | Volume: 10 | Issue: 6 | Pages: 844-852
Abstract There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). The research on SCD in early AD, however, is limited by the absence of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD‐I) addressed this deficiency by reaching consensus on terminology and on a conceptual framework for research on SCD in AD. In this publication, research criteria for SCD in pre‐mild cognitive impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings. Finally, a set of features is presented, which in accordance with current knowledge, increases the likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as SCD plus .
Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI
Visser, Pieter Jelle , Knopman, David S.
Neurology | July 30, 2009 | Volume: 73 | Issue: 10 | Pages: 744-745
Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned?
Grundman, Michael, Petersen, Ronald C. , Bennett, David A. , Feldman, Howard , Salloway, Stephen , Thal, Leon J., Schenk, Dale, Khachaturian, Zaven S., Thies, William, Visser, Pieter Jelle , Bennett, David A. , Feldman, Howard H
Alzheimer's & Dementia | June 14, 2006 | Volume: 2 | Issue: 3 | Pages: 220-233
The biological changes that occur in the brains of Alzheimer's disease (AD) patients are thought to begin long before the onset of clinical symptoms. Although current therapeutic agents have been approved only for patients with mild to moderate AD, Alzheimer‐type pathology in patients with mild to moderate AD is already quite advanced. One impetus for the development of the concept of mild cognitive impairment (MCI) was the attempt to recognize AD early in its clinical expression and to determine whether it is possible through therapeutic interventions to improve the memory impairment at this stage or delay further progression to dementia. To this end, several clinical trials have been conducted in patients with MCI. On September 8 and 9, 2004 a meeting of the Alzheimer's Association Research Roundtable was held at which experts in the field of MCI convened to review the collective experience from these trials and to consider potential approaches that might improve MCI clinical trials in the future. This article summarizes the presentations and discussions of that meeting.